Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection

Journal of Clinical Pharmacology

Volumn 45, Issue 3, 2005, Pages 275-285

  Aora, Sanjee ^b   Xu, Christine ^a   Teng, Alice ^a   Peterson, Janet ^a   Yeh, Li Tain ^a   Gish, Robert ^c   Lau, Daryl ^d   Rossi, Stephen ^e   Lin, Chin Chung ^a,f  

^a Valeant Research and Development   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Valeant Pharmaceuticals International   (United States)

Author keywords

Hepatitis C; Pharmacokinetics; Ribavirin; Viramidine

Indexed keywords

PLACEBO; RIBAMIDINE; RIBAVIRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERYTHROCYTE LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FATIGUE; FEMALE; HEADACHE; HEMOLYSIS; HEPATITIS C; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NAUSEA; OPEN STUDY; STEADY STATE; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; ERYTHROCYTES; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PRODRUGS; RIBAVIRIN;

EID: 16844364646     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004270152     Document Type: Article

References (20)

1. Sidwell RW, Huffman JH, Khare LB, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of virazole:1-beta-D ribofuranosyl-1,2,4- triazole-3-carboxamide. Science. 1972;177:705-706.
2. Stephen E, Jones CJ, Peters CJ, Eddy GA, Loizeaux PS, Jahrling PB. Ribavirin treatment of Toga-, Aren-, and Bunya virus infections in subhuman primates and other laboratory species. In: Smith RA, Kirkpatrick W, eds. Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press; 1980.
3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
4. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
5. Manns MP, McHutchison JG, Gordon SC, et al, and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965.
6. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;26;347:975-982.
8. Ferrara EA, Oishi JS, Wannemacher RW, Stephen EL. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother. 1981;19:1042-1049.
9. Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kalman CM, Connor JD, Robert RB. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1987;41:546-555.
10. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem. 1990;22:379-383.
11. Lertora JJ, Rege AB, Lacour JT, et al. Pharmacokinetics and longterm tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1991;50:442-449.
12. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety and tolerance and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infections. Antimicrob Agents Chemother. 1993;37:532-539.
13. Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother. 2003;47:426-431.
14. Lin CC, Lau JYN. Evaluation of ribavirin and viramidine, a prodrug of ribavirin for hemolytic anemia potential using in-vitro partition experiment. Poster presented at: 52nd Annual Meeting, American Association for the Study of Liver Diseases; November 2001; Dallas, Tex. Abstract 178.
15. Lau JYN, Lin CC. Evaluation of selective liver delivery of ribavirin and viramidine, a prodrug of ribavirin, using whole body autoradiography. Poster presented at: 52nd Annual Meeting, American Association for the Study of Liver Diseases; November 2001; Dallas, Tex. Abstract 1021.
16. Lin CC, Yeh LT, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antiviral Chem Chemother. 2003;14:145-152.
17. Lin CC, Luu K, Lourenco D, Huang J, Fang JW, Lau JYN. Comparative absorption, metabolism and excretion studies of ribavirin versus viramidine, a liver-targeting prodrug. Poster presented at: 52nd Annual Meeting, American Association for the Study of Liver Diseases; November 2001; Dallas, Tex. Abstract 182.
18. Lin CC, Philip L, Xu C, Yeh LT. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol. 2003;44:265-275.
19. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999;1(suppl 1):17-24.
20. Lin CC, Xu C, Teng A, Yeh LT, Peterson J. Dosing with viramidine in HCV patients resulted in lower plasma and RBC ribavirin levels and exhibited a smaller decreases in hemoglobin compared to ribavirin dosing. Poster presented at: 55th Annual Meeting, American Association for the Study of Liver Diseases; October 2004; Boston, Mass. Abstract 517.